News


28th May 2024

Immunosis attends Clinical Immunology Society Annual Meeting in Minneapolis to present additional data from clinical study

The entire Immunosis team was in Minneapolis this May to attend the Clinical Immunology Society Annual Meeting. Our CSO, Ben Cocks, presented our results alongside Senior Scientist Emma Gail during a lively poster session. You can read our abstract below or through the Clinical Immunology supplement link:

https://www.sciencedirect.com/science/article/abs/pii/S1521661624001785


25th August 2023

Boost for Immunosis to commercialise diagnosis of diseases driven by immune dysregulation

We are pleased to announce Immunosis has been selected as a recipient of the highly competitive ANDHealth+ award for 2023.

Immunosis is delighted to work with ANDHealth to further develop and commercialise our technology including our lead product, PrimDx, a diagnostic test for patients with primary immunodeficiency.

We are working to establish our RNA-based platform technology for understanding and diagnosing diseases driven by immune dysregulation. As part of the ANDHealth+ program, Immunosis plans to conduct a clinical validation study in Australia and the USA in patients prone to repeated sinus and respiratory infections and develop a reimbursement strategy to offset the cost of testing for patients. These steps are critical for the commercialisation of PrimDx in global markets.

The ANDHealth+ program supports and funds digital health companies such as Immunosis to accelerate commercialisation of their platforms. The program is funded by the Australian Government’s Medical Research Future Fund (MRFF).
For more information, please visit the following link:

Read a statement from our CEO, Simon Green, here as well as about the program: https://www.andhealth.com.au/news/five-promising-digital-health-companies-selected-to-scale-exciting-new-australian-health-technologies


19th June 2023

Immunosis presents latest data at CIS 2023

CSO Prof. Ben Cocks and senior scientist Dr Emma Gail attended the Clinical Immunology conference in St. Louis this year, learning about the latest research in the field and meeting with leading clinicians and researchers. Dr Gail presented the work from our first clinical study in the poster titled “Identifying patients with primary immunodeficiency using statistical modelling of unique genetic signatures from transcriptomic data” You can view the full poster here:

Read our abstract published in the supplement in the May 2023 issue of Clinical Immunology: https://www.sciencedirect.com/science/article/pii/S1521661623002656


29th March 2023

Immunosis presenting and looking to collaborate at CIS 2023

Immunosis' Senior Scientist Dr Emma Gail and CSO Prof Ben Cocks will be attending the 2023 Clinical Immunology Society meeting in St Louis MO USA May 18-21. 

Dr Gail will be presenting data on the potential of transcriptomics to better identify and characterise patients with Primary Immune Deficiency (PID). 

The new results for our diagnostic test, Prim-Dx, have been generated through collaborations with the Walter and Eliza Hall Institute of Medical Research, Royal Children’s Hospital, Murdoch Children’s Research Institute, and the Royal Melbourne Hospital.

Immunosis CEO Dr Simon Green said “Immunosis are looking forward to welcoming discussion with leading clinicians and investigators on expanding transcriptomic studies for PID complementing other clinical studies". 

Abstract is titled: Using statistical modelling to better identify primary immunodeficiency using a unique genetic signature from transcriptomic data 

 


20th February 2023

Immunosis has appointed Professor Ben Cocks as Chief Scientific Officer.

Ben joins Immunosis bringing more than 30 years of experience in biotech industries and extensive leadership experience developing cross-functional relationships and research impact. Most recently, Ben has been Research Director Genomics and Cellular Sciences in DJPR based at La Trobe University leading a team expert in using genomic and epigenetic tools for prediction.

In addition to genomics applications, Ben’s prior experience includes immune system discoveries including new pathways determining the development of parasitic, viral, and inflammatory diseases, and SLAM as a key receptor important for T and B cell function.

Ben says “I am excited to join Immunosis to develop better diagnosis of immune dysregulation with epigenetic information”. 

2nd June 2022

The Hon Jaala Pulford announced today a grant of $100k to fund clinical trial work with the aim of developing the Immunosis diagnostic technolgy for patients with Primary Immune Deficiency.

Both patients and healthy controls are currently being recruited for the study.

https://www.premier.vic.gov.au/site-4/faster-diagnosis-possible-new-clinical-trial


© Immunosis Pty Ltd (ABN 35 609 513 162).
All rights reserved.
Powered by Red Onion Creative.